低分子肝素钙治疗早发型重度子痫前期临床疗效观察

The clinical effect of low molecular heparin calcium on early onset severe pre-eclampsia

目的观察低分子肝素钙治疗早发型重度子痫前期临床疗效。方法选取孕龄26—34周重度子痫前期患者60例，分为观察组28例和对照组32例，观察组在常规治疗基础上加用低分子肝素钙，对比两组治疗后延长孕龄时间、脐动脉S／D比值、羊水指数、胎盘重量、新生儿体质量及Apgar评分间的差异。结果平均延长孕龄时间观察组与对照组比较差异有统计学意义[（10．19±4．57）d与（6．14±3．56）d，t=3．872，P〈0．01]。脐动脉S／D比值、羊水指数、胎盘重量、新生儿体质量，两组比较差异均有统计学意义（t值分别为9．056、5．259、2．157，2．027；P〈0．01，〈0．05）。1分钟及5分钟新生儿Apgar评分提高，两组比较差异均有统计学意义（X2值分别为8．058、7．190，P均〈0．01）。结论应用低分子肝素钙治疗早发型重度子痫前期可延长孕龄，增加新生儿体质量，有效改善新生儿预后。

Objective To analyze the clinical effects of low molecular heparin calcium on early onset severe pre-eelampsia. Methods Sixty patients with early onset severe pre-eclampsia at 26 -34 weeks of gestational age were divided into treatment group （28 cases） and control group （ 32 cases）. The conventional treatment was delivered in control group and low molecalar heparin calcium （LMWHC） was used in treatment group additionally. The time of prolonged gestational age, umbilical arterial S/D ratio, amniotic fluid index, placenta weight,neonatal weight and Apgar score were measured in two groups. Results The time of prolonged gestational age was 10. 19 ± 4. 57days in treatment group and 6. 14 ± 3.56 days in control group, which were significantly different （ P 〈 0.01 ） . Umbilical arterial S/D ratio, amniotic fluid index, placenta weight and neonatal weight were all significantly different between the two groups （ P 〈 0. 05 ）. Neonatal Apgar score in treatment group was remarkably improved （ P 〈 0. 01 ）. Conclusion LMWHC treatment in the patients with early onset severe pre-eelampsia could extend gestational age, increase neonatal weight and improve perinatal outcomes.